Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.

Saved in:
Bibliographic Details
Published inBlood Vol. 144; no. 5; pp. 581 - 585
Main Authors Cook, Jacqueline A., Lott, Loren, Perry, Jenna, Eckel, Ashley M., Xu, Dongbin, Hudson, Chad A., Wells, Denise A., Loken, Michael R., Menssen, Andrew J.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2024
Subjects
Core Binding Factor Alpha 2 Subunit - genetics
Core Binding Factor Alpha 2 Subunit - metabolism
Female
Flow Cytometry - methods
Humans
In Situ Hybridization, Fluorescence
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - metabolism
Leukemia, Myeloid, Acute - pathology
Male
Mast Cells - metabolism
Mast Cells - pathology
Neoplasm, Residual - diagnosis
Oncogene Proteins, Fusion - genetics
Oncogene Proteins, Fusion - metabolism
RUNX1 Translocation Partner 1 Protein - genetics
RUNX1 Translocation Partner 1 Protein - metabolism
Online AccessGet full text

Cover

More Information
Summary:Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood.2024024264